Table of Contents
To view the fulltext, log-in or choose pay-per-view options:
Get Access

Gelatinous Transformation of Bone Marrow in Chronic Myeloid Leukemia during Treatment with Imatinib Mesylate: A Disease or a Drug Effect?

Ram R.a, c · Gafter-Gvili A.a, c · Okon E.b, c · Pazgal I.a, c · Shpilberg O.a, c · Raanani P.a, c
aInstitutes of Hematology and bPathology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, and cSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Acta Haematol 2008;119:104–107 (DOI:10.1159/000121825)


Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.


Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00